JP2023502782A - 星状細胞からニューロンへのＮｅｕｒｏＤ１媒介性変換を介した外傷性脳損傷後の脳の修復 - Google Patents

星状細胞からニューロンへのＮｅｕｒｏＤ１媒介性変換を介した外傷性脳損傷後の脳の修復 Download PDF

Info

Publication number
JP2023502782A
JP2023502782A JP2022530253A JP2022530253A JP2023502782A JP 2023502782 A JP2023502782 A JP 2023502782A JP 2022530253 A JP2022530253 A JP 2022530253A JP 2022530253 A JP2022530253 A JP 2022530253A JP 2023502782 A JP2023502782 A JP 2023502782A
Authority
JP
Japan
Prior art keywords
neurod1
neurons
seq
nucleic acid
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502782A5 (https=
JPWO2021108609A5 (https=
Inventor
チェン，ゴン
レイ，ジョウ－ファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of JP2023502782A publication Critical patent/JP2023502782A/ja
Publication of JP2023502782A5 publication Critical patent/JP2023502782A5/ja
Publication of JPWO2021108609A5 publication Critical patent/JPWO2021108609A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022530253A 2019-11-25 2020-11-25 星状細胞からニューロンへのＮｅｕｒｏＤ１媒介性変換を介した外傷性脳損傷後の脳の修復 Pending JP2023502782A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939978P 2019-11-25 2019-11-25
US62/939,978 2019-11-25
PCT/US2020/062299 WO2021108609A1 (en) 2019-11-25 2020-11-25 Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion

Publications (3)

Publication Number Publication Date
JP2023502782A true JP2023502782A (ja) 2023-01-25
JP2023502782A5 JP2023502782A5 (https=) 2023-12-01
JPWO2021108609A5 JPWO2021108609A5 (https=) 2023-12-01

Family

ID=76130727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530253A Pending JP2023502782A (ja) 2019-11-25 2020-11-25 星状細胞からニューロンへのＮｅｕｒｏＤ１媒介性変換を介した外傷性脳損傷後の脳の修復

Country Status (6)

Country Link
EP (1) EP4065227A4 (https=)
JP (1) JP2023502782A (https=)
CN (1) CN115135382A (https=)
AU (1) AU2020391479A1 (https=)
CA (1) CA3162891A1 (https=)
WO (1) WO2021108609A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143163A1 (ja) * 2023-12-27 2025-07-03 アステラス製薬株式会社 側鎖に環状基を有するカルバモイル脂質、その脂質ナノ粒子、及びその医薬組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120418229A (zh) * 2022-12-28 2025-08-01 安斯泰来制药株式会社 4-氨基哌啶化合物、其脂质纳米粒子和含有其的药物组合物
WO2024162304A1 (ja) * 2023-01-31 2024-08-08 アステラス製薬株式会社 環状アミンを有するカルバモイル脂質又はウレア脂質、それを含む脂質ナノ粒子、及び医薬組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000295987A (ja) * 1999-01-20 2000-10-24 Cedars Sinai Medical Center トランスフェクトされた上皮基底細胞の神経原細胞（ｎｅｕｒａｌｐｒｏｇｅｎｉｔｏｒｃｅｌｌ）、ニューロン細胞および／またはグリア細胞への分化転換
US20140024599A1 (en) * 2012-07-19 2014-01-23 The Penn State Research Foundation Methods and compositions for treatment of disease or injury of the nervous system
JP2017503849A (ja) * 2013-10-25 2017-02-02 ウェイン ステート ユニバーシティー タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物
US20170239373A1 (en) * 2016-02-18 2017-08-24 The Penn State Research Foundation GENERATING GABAergic NEURONS IN BRAINS
WO2018160712A1 (en) * 2017-02-28 2018-09-07 The Penn State Research Foundation Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow
WO2019152857A1 (en) * 2018-02-02 2019-08-08 Gong Chen Methods and materials for treating brain injuries

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903933C (en) * 2015-09-11 2020-02-25 Nomadogen Biotechnologies Inc. Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
US9840542B2 (en) * 2015-09-11 2017-12-12 Nomadogen Biotechnologies Inc. Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000295987A (ja) * 1999-01-20 2000-10-24 Cedars Sinai Medical Center トランスフェクトされた上皮基底細胞の神経原細胞（ｎｅｕｒａｌｐｒｏｇｅｎｉｔｏｒｃｅｌｌ）、ニューロン細胞および／またはグリア細胞への分化転換
US20140024599A1 (en) * 2012-07-19 2014-01-23 The Penn State Research Foundation Methods and compositions for treatment of disease or injury of the nervous system
JP2017503849A (ja) * 2013-10-25 2017-02-02 ウェイン ステート ユニバーシティー タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物
US20170239373A1 (en) * 2016-02-18 2017-08-24 The Penn State Research Foundation GENERATING GABAergic NEURONS IN BRAINS
WO2018160712A1 (en) * 2017-02-28 2018-09-07 The Penn State Research Foundation Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow
WO2019152857A1 (en) * 2018-02-02 2019-08-08 Gong Chen Methods and materials for treating brain injuries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CELL STEM CELL, vol. vol.14, issue 2, JPN6022050458, 2014, pages 188 - 202, ISSN: 0005468983 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143163A1 (ja) * 2023-12-27 2025-07-03 アステラス製薬株式会社 側鎖に環状基を有するカルバモイル脂質、その脂質ナノ粒子、及びその医薬組成物

Also Published As

Publication number Publication date
CN115135382A (zh) 2022-09-30
CA3162891A1 (en) 2021-06-03
WO2021108609A1 (en) 2021-06-03
AU2020391479A1 (en) 2022-06-16
EP4065227A4 (en) 2023-12-20
EP4065227A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
US20240082352A1 (en) Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow
US11167044B2 (en) Regenerating functional neurons for treatment of disease in the nervous system
US20210032300A1 (en) Methods and materials for treating brain injuries
JP2023502782A (ja) 星状細胞からニューロンへのＮｅｕｒｏＤ１媒介性変換を介した外傷性脳損傷後の脳の修復
JP2025184866A (ja) 脊髄損傷およびａｌｓの治療のための機能的ニューロンの再生
US20220160825A1 (en) Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
US20240325488A1 (en) Regenerating functional neurons for treatment of hemorrhagic stroke
HK40078350A (en) Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow
JP2025184865A (ja) 神経学的障害の治療のための機能的ニューロンの再生

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250708